2B70:XETRA:XETRA-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 5.034

Change

-0.05 (-0.91)%

Market Cap

USD 0.52B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-17 )

ETFs Containing 2B70:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.48% 17% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.48% 20% F 20% F
Trailing 12 Months  
Capital Gain -8.99% 15% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.99% 18% F 23% F
Trailing 5 Years  
Capital Gain -0.36% 25% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.36% 26% F 28% F
Average Annual (5 Year Horizon)  
Capital Gain 3.75% 40% F 42% F
Dividend Return 3.75% 39% F 40% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 12.01% 52% F 61% D-
Risk Adjusted Return 31.21% 33% F 38% F
Market Capitalization 0.52B 72% C 55% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.